FDA partially halts Sanofi’s BTK inhibitor for multiple sclerosis, myasthenia gravis FDA/Regulatory, R&D, Therapeutics The agency’s decision came after researchers found cases of drug-induced liver injury in some patients. Read more June 30, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/04/Sanofi-logo.webp 800 1200 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-06-30 09:59:512022-06-30 12:26:48FDA partially halts Sanofi's BTK inhibitor for multiple sclerosis, myasthenia gravis
